<DOC>
	<DOCNO>NCT01926847</DOCNO>
	<brief_summary>Patients Raynaud 's phenomenon suffer painful attack trigger stress cold cause acute lower blood flow digit . In trial safety efficacy well effect one dose sGC stimulator Riociguat digital blood flow measure cold exposure test patient suffer Raynaud 's phenomenon . Measurements two period compare : one period patient give active drug period placebo .</brief_summary>
	<brief_title>Digital Flow Enhancement Raynaud 's Phenomenon With sGC ( Soluble Guanylate Cyclase ) Stimulator</brief_title>
	<detailed_description />
	<mesh_term>Raynaud Disease</mesh_term>
	<criteria>Patients suffer Raynaud 's phenomenon diagnose least â‰¥1 year begin study follow origin : idiopathic ( primary ) limit cutaneous Scleroderma associate diffuse cutaneous Scleroderma associate mixed connective tissue disease associate Patients take medication interfere digital flow measurement calcium channel blocker ( CCB ) , phosphodiesterase 5 ( PDE5 ) inhibitor , endothelin receptor antagonist ( ERA ) , Nitrates Smokers Systolic blood pressure ( SBP ) 105mmHg rest</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Digital ischemia</keyword>
	<keyword>Raynaud 's phenomenon</keyword>
</DOC>